Clinical Trials Browser

Phase 2 × Hormone Sensitive Prostate Cancer × 90 days × Clear all

NCT04126070 2026-01-22

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

Phase 2 Active not recruiting

Hormone Sensitive Prostate Cancer